BMIQ1
MCID: BDY007
MIFTS: 42

Body Mass Index Quantitative Trait Locus 1 (BMIQ1)

Categories: Bone diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 56 13
Body Mass Index 56 17
Bmi 56 47
Body Mass Index; Bmi 56
Bmiq1 56

Classifications:



External Ids:

OMIM 56 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM : 56 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 3 and body mass index quantitative trait locus 2. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Telmisartan and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and liver.

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1113)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 3 12.7
2 body mass index quantitative trait locus 2 12.7
3 body mass index quantitative trait locus 5 12.7
4 body mass index quantitative trait locus 6 12.7
5 body mass index quantitative trait locus 13 12.7
6 body mass index quantitative trait locus 15 12.7
7 esophageal cancer 11.9
8 chromosome 16p11.2 deletion syndrome, 220-kb 11.5
9 siddiqi syndrome 11.5
10 hypercholesterolemia, familial, 3 11.3
11 mental retardation, x-linked 12 11.2
12 morbid obesity and spermatogenic failure 11.2
13 chronic kidney disease 10.7
14 arteries, anomalies of 10.7
15 hyperlipoproteinemia, type iii 10.7
16 lipoprotein quantitative trait locus 10.7
17 kidney disease 10.7
18 hypercholesterolemia, familial, 1 10.6
19 pulmonary disease, chronic obstructive 10.6
20 end stage renal disease 10.6
21 eclampsia 10.6
22 rectum cancer 10.6
23 renal cell carcinoma, nonpapillary 10.6
24 pustulosis of palm and sole 10.6
25 psoriasis 10.6
26 congestive heart failure 10.5
27 atrial fibrillation 10.5
28 ovarian cancer 10.5
29 diabetes mellitus 10.5
30 pancreatic cancer 10.5
31 acute myocardial infarction 10.5
32 back pain 10.5
33 asthma 10.5
34 ischemia 10.5
35 ige responsiveness, atopic 10.5
36 adenocarcinoma 10.5
37 prostate cancer 10.5
38 myocardial infarction 10.5
39 rickets 10.5
40 lung cancer 10.5
41 hyperandrogenism 10.5
42 hypothyroidism 10.5
43 precocious puberty 10.5
44 thyroid carcinoma 10.5
45 rheumatoid arthritis 10.4
46 fatty liver disease, nonalcoholic 1 10.4
47 hyperuricemia 10.4
48 central precocious puberty 10.4
49 alzheimer disease 10.4
50 hepatocellular carcinoma 10.4

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM:

606641

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1041)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Rutin Approved, Experimental, Investigational Phase 4 153-18-4 5280805
6
Menthol Approved Phase 4 2216-51-5 16666
7
Borage oil Approved, Investigational Phase 4
8
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
9
Succinylcholine Approved Phase 4 306-40-1 5314
10
Nifedipine Approved Phase 4 21829-25-4 4485
11
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
12
Atenolol Approved Phase 4 29122-68-7 2249
13
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Sertraline Approved Phase 4 79617-96-2 68617
19
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
24
Ethambutol Approved Phase 4 74-55-5 3279 14052
25
Lorazepam Approved Phase 4 846-49-1 3958
26
Ziprasidone Approved Phase 4 146939-27-7 60854
27
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
28
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
29
Desflurane Approved Phase 4 57041-67-5 42113
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
31
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
32
Memantine Approved, Investigational Phase 4 19982-08-2 4054
33
Vancomycin Approved Phase 4 1404-90-6 14969 441141
34
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
35
Drospirenone Approved Phase 4 67392-87-4 68873
36
Sulbactam Approved Phase 4 68373-14-8
37
Sultamicillin Approved, Investigational Phase 4 76497-13-7
38
Voriconazole Approved Phase 4 137234-62-9 71616
39
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
40
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
41
Fenofibrate Approved Phase 4 49562-28-9 3339
42
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
43
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
44
Nadroparin Approved, Investigational Phase 4
45
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
46
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
47
Glyburide Approved Phase 4 10238-21-8 3488
48
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
49
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
50
Valsartan Approved, Investigational Phase 4 137862-53-4 60846

Interventional clinical trials:

(show top 50) (show all 4054)
# Name Status NCT ID Phase Drugs
1 A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
2 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
3 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
4 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
5 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
6 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
7 Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol Unknown status NCT00611780 Phase 4
8 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
9 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
10 Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery Unknown status NCT01432769 Phase 4
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
13 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
14 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
15 Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension Unknown status NCT02894723 Phase 4
16 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
17 A Double-blind, Randomized, Controlled, Equivalence Study Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections Unknown status NCT02612272 Phase 4 Ketorolac;Betamethasone
18 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
19 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
20 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
21 The Effect of Body Mass Index, Intra-abdominal Pressure, Abdominal Girth and Waist Circumference on Sensory Block Level After Single-shot Spinal Anesthesia for Cesarean Section Unknown status NCT03164096 Phase 4 Bupivacaine Hydrochloride
22 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
23 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
24 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
25 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
26 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
27 Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
28 The Need of Dosing Adjustment for Simvastatin in Obese Patients Post Bariatric Surgery- Laparoscopic Sleeve Gastrectomy (LSG) Unknown status NCT03571802 Phase 4 Simvastatin
29 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
30 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
31 Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
32 Irritation and Anal Bleeding in Patients Affected by Hemorrhoids: Comparative Evaluation of Three Different Treatments. Unknown status NCT03569930 Phase 4 flavonoid-based supplements;Centella Complex
33 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
34 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4
35 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
36 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
37 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
38 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
39 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
40 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
41 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
42 Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial Unknown status NCT02930057 Phase 4 Celestone;Control
43 Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty Unknown status NCT03359525 Phase 4 Tranexamic Acid
44 Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
45 The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes Completed NCT00778622 Phase 4 Metformin XR
46 Improving Contraceptive Effectiveness in Obese Women Completed NCT01170390 Phase 4 All participants (Aviane);Portia;Aviane
47 Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease Completed NCT00934570 Phase 4 Metformin and standard exercise;Metformin Intensive exercise
48 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
49 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
50 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

40
Breast, Heart, Liver, Bone, Kidney, Ovary, Testes

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 30006)
# Title Authors PMID Year
1
Genetic studies of body mass index yield new insights for obesity biology. 56 61
25673413 2015
2
New genetic loci link adipose and insulin biology to body fat distribution. 56 61
25673412 2015
3
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 56 61
21706003 2011
4
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. 56 61
20935630 2010
5
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. 61 56
14569127 2003
6
A study of linkage and association of body mass index in the Old Order Amish. 56 61
12888987 2003
7
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. 61 56
12355400 2002
8
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. 61 56
11713718 2002
9
Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Québec family study. 61 56
10096693 1999
10
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 56 61
9806549 1998
11
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. 56 61
9758619 1998
12
The genetic contribution to non-syndromic human obesity. 56
19506576 2009
13
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 56
19151714 2009
14
Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. 56
17855449 2007
15
Genetic pleiotropy between asthma and obesity in a community-based sample of twins. 56
16337451 2005
16
Genome-wide scan of obesity in the Old Order Amish. 56
11238509 2001
17
Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 56
10523018 1999
18
Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. 61
32249013 2020
19
Healthier school food and physical activity environments are associated with lower student body mass index. 61
32509507 2020
20
A novel approach to anthropometric assessment for geographically dispersed samples: A pilot study. 61
32509510 2020
21
Beta-hemolytic group a streptococcal orthopaedic infections: Our institutional experience and review of the literature. 61
32255996 2020
22
On interactions between body mass index, type of anticoagulation and outcomes. 61
32505328 2020
23
The effects of body mass index on operative time and outcomes in nipple-sparing mastectomy. 61
31870533 2020
24
Evidence-based nipple-sparing mastectomy in patients with higher body mass index: Recommendations for a successful standardized surgery. 61
31928777 2020
25
Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: A systematic review and dose-response meta-analysis of cohort studies among four million participants. 61
32454303 2020
26
Low body mass index has minimal impact on plasma levels of cytokines and chemokines in tuberculous lymphadenitis. 61
32420460 2020
27
Characteristics of newly diagnosed adults with type 1 diabetes in the UK and evolution of glycaemic control, body mass index and Charlson comorbidity index over the first 5 years after diagnosis. 61
31668975 2020
28
The U-shaped association between body mass index and gastric cancer risk in the Helicobacter pylori Biomarker Cohort Consortium: A nested case-control study from eight East Asian cohort studies. 61
31745972 2020
29
Body-related attentional bias as mediator of the relationship between body mass index and body dissatisfaction. 61
32155304 2020
30
Levator ani muscle (LAM) anatomical volume compared to age and body mass index (BMI) of patients. 61
31792593 2020
31
Relationship of body mass index, serum creatine kinase, and acute kidney injury after severe trauma. 61
32282754 2020
32
Body mass index: Another way to predict the efficacy of immune checkpoint inhibitors? 61
32320929 2020
33
Weighing on us all? Quantification and cultural responses to obesity in NHS Britain. 61
31018707 2020
34
Can adipokine visfatin be a novel marker of pregnancy-related disorders in women with obesity? 61
32220005 2020
35
Prepregnancy body mass indexes are associated with perinatal outcomes in females with preeclampsia. 61
32509020 2020
36
State, but not trait gratitude is associated with cardiovascular responses to acute psychological stress. 61
32251630 2020
37
Obesity is associated with worse long-term outcomes in hypertrophic cardiomyopathy patients with acute myocardial infarction. 61
31674878 2020
38
Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. 61
32423697 2020
39
Population Pharmacokinetics of Cefoxitin Administered for Pediatric Cardiac Surgery Prophylaxis. 61
32221166 2020
40
Body mass index, residual psychotic symptoms, and inflammation associated with brain volume reduction in older patients with schizophrenia. 61
32128879 2020
41
The interaction between detectable plasma viral load and increased body mass index on hypertension among persons living with HIV. 61
31530006 2020
42
Risk of severe maternal morbidity in relation to prepregnancy body mass index: Roles of maternal co-morbidities and caesarean birth. 61
31106879 2020
43
Multifaceted genome-wide study identifies novel regulatory loci in SLC22A11 and ZNF45 for body mass index in Indians. 61
32363570 2020
44
Sexual Risk Behaviors during Adolescence: Associations with Childhood and Adolescent BMI. 61
31983033 2020
45
An Examination of Adolescents' Values in a Motivational Interviewing-based Obesity Intervention. 61
32553032 2020
46
Surgical tracheostomies in COVID-19 patients: A multidisciplinary approach and lessons learned. 61
32389538 2020
47
Annual report of the Japanese Breast Cancer Society registry for 2016. 61
32394414 2020
48
Relationship between exercise capacity and depressive symptoms in community-dwelling older adults. 61
32388071 2020
49
Cross-sectional area in median and ulnar nerve ultrasound correlates with hand volume. 61
32270519 2020
50
Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors. 61
31404666 2020

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....